| Inhibition of 5-lipoxygenase - BioAssay Summary A novel class of 5-lipoxygenase (5-LO) inhibitors characterized by a central imidazo[1,2-a]pyridine scaffold, a cyclohexyl moiety and an aromatic system, is presented. This scaffold was identified in a virtual screening study and exhibits promising inhibitory potential on the 5-LO. Here, we investigate the structure-activity relationships of this compound class. With more .. |
_ | |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BioActive Compound: 1 Description: Title: SAR-study on a new class of imidazo[1,2-a]pyridine-based inhibitors of 5-lipoxygenase. Abstract: A novel class of 5-lipoxygenase (5-LO) inhibitors characterized by a central imidazo[1,2-a]pyridine scaffold, a cyclohexyl moiety and an aromatic system, is presented. This scaffold was identified in a virtual screening study and exhibits promising inhibitory potential on the 5-LO. Here, we investigate the structure-activity relationships of this compound class. With N-cyclohexyl-6-methyl-2-(4-morpholinophenyl)imidazo[1,2-a]pyridine-3-amine (14), we identified a potent 5-LO inhibitor (IC(50)=0.16##M (intact cells) and 0.1##M (cell-free)), which may possess potential as an effective lead compound intervening with inflammatory diseases and certain types of cancer. (PMID: 22326163) Comment Compounds with activity <= 50uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation. Putative Target: ChEMBL Target ID: 55 Target Type: SINGLE PROTEIN Pref Name: Arachidonate 5-lipoxygenase Description: Arachidonate 5-lipoxygenase Organism: Homo sapiens Tax ID: 9606 Confidence: Homologous single protein target assigned Relationship Type: Homologous protein target assigned ChEMBL target type: Target is a single protein chain Categorized Comment ChEMBL Assay Type: Binding ChEMBL Assay Data Source: Scientific Literature Result Definitions
* Activity Concentration. Data Table (Concise)
PageFrom: |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||